Program
This event has been certified by the German Regional Medical Chamber.
You will receive 7 continuing education points for your attendance on Friday and 7 continuing education points for your attendance on Saturday.
The networking dinner planned for Friday evening at the Restaurant Palais Prince Carl had to be cancelled due to organizational reasons.
Friday, April 5th 2019
Coffee and snacks provided at the lobby
Registration at the lobby
Introduction and Opening Remarks - 7th Heidelberg Myeloma Workshop
Hartmut Goldschmidt, Heidelberg
Marc S. Raab, Heidelberg
Carsten Müller-Tidow, Heidelberg
Stefan Fröhling, Heidelberg
Michael Baumann, Heidelberg
Annette Grüters-Kieslich, Heidelberg
Session I
Diagnostics and Prognostic Factors
Moderator: Siegfried Janz, Milwaukee
Major Prognostic Factors in Patients with SMM and MM
Herve Avet-Loiseau, Toulouse
Discussion
Novel Imaging Techniques in Multiple Myeloma
Jens Hillengaß, Buffallo
Discussion
Current and Future Concepts in PET - Imaging
Martin Kortüm, Würzburg
Discussion
Biology of High-Risk Myeloma “del17p Myeloma: Biology and Prognosis”
Anjan Thakurta, Summit
Discussion
Key Note Lecture
Introducing Shaji Kumar (Marc S. Raab)
How to Define and when to Treat Smoldering Multiple Myeloma
Shaji Kumar, Rochester
Discussion
Coffee Break - Drinks, Snacks and Small Appetizers
Session II
Role of Immunotherapy in Multiple Myeloma
Moderator: Michael Schmitt, Heidelberg
Myeloma Biology: Basic Principles of Immunotherapy
Paola Neri, Calgary
Discussion
Antibodies in Myeloma: Clinical Efficacy and Management
Niels van de Donk, Amsterdam
Discussion
Innovative Immunotherapies Including Car-T Cells
Adam D. Cohen, Philadelphia
Discussion
Key Note Lecture
Introducing Brian Durie (Hartmut Goldschmidt)
MRD - Negativity for all Patients
Brian Durie, Los Angeles
Discussion
Coffee Break - Drinks, Snacks and Small Appetizers
Session III
Current Therapy of Multiple Myeloma
Moderator: Heinz Ludwig, Wien
First-line Therapy for Non-Transplant Eligible Patients
Katja Weisel, Tübingen
Discussion
Updated Results on Double Transplant in First-line
Michele Cavo, Bologna
Discussion
Treatment of High-Risk Myeloma
Nicola Giesen, Heidelberg
Discussion
The Role of Allogeneic Transplantation
Nicolaus Kröger, Hamburg-Eppendorf
Discussion
When and How to Treat Relapsed Multiple Myeloma
Christof Scheid, Köln
Discussion
Summary - Day one
Hartmut Goldschmidt, Heidelberg
Saturday, April 6th 2019
Key Note Lecture
Introducing Kenneth Anderson (Marc S. Raab)
The Future of Myeloma Therapy in the Next Decade
Kenneth C. Anderson, Boston
Discussion
DEBATE: MRD Driven Therapy - Ready for Primetime
Moderator: Michael Hundemer, Heidelberg
Molecular Techniques for Detection of MRD - Feasibility and Reliability
Stefanie Huhn, Heidelberg
Discussion
YES: MRD Negativity is a Strong Predictor of Clinical Outcomes
Ola Landgren, Bethesda
Discussion
NO: Lack of Standardization Suggests it is not yet a Standard of Care in Clinical Practice
Martin Kaiser, London
Discussion
Session IV
Biology and Genomics of Multiple Myeloma
Moderator: Aldo M. Roccaro, Brescia
Radiogenomics
Leo Rasche, Würzburg
Discussion
Genetic Heterogeneity and Genomic Evolution
Niels Weinhold, Heidelberg
Discussion
Non-Evasive Techniques for Detection
Bruno Paiva, Pamplona
Discussion
Analyzing the Single Myeloma Cell
Jens G. Lohr, Boston
Discussion
Key Note Lecture
Introducing Bart Barlogie (Niels Weinhold)
The Road to Cure in Multiple Myeloma
Bart Barlogie, New York
Lunch - Buffet
Session V
Novel Concepts
Moderator: Christoph Driessen, St. Gallen
Development of Personalized Medicine in Multiple Myeloma
Keith Stewart, Rochester
Discussion
Emerging Drugs and Targets
Marc S. Raab, Heidelberg
Discussion
ProTACs - Targeting the Undrugables?
Nizar Bahlis, Calgary
Discussion
AL Amyloidosis – Organ Responses to Novel Therapies
Stefan Schönland, Heidelberg
Discussion
Deutsche Studiengruppe Multiples Myelom
Current and Novel Trials of DSMM
Stefan Knop, Würzburg
Discussion
German-speaking Myeloma Multicenter Group
Current and Novel Trials of GMMG
Hartmut Goldschmidt, Heidelberg
Discussion
Summary of the 7th Heidelberg Myeloma Workshop
Hartmut Goldschmidt, Heidelberg